Search
for

    Glossary Nivolumab

    immunotherapy drug that helps immune system attack cancer cells

    Nivolumab, also known by the brand name Opdivo, is an immunotherapy drug used to treat various types of cancer. It works by blocking a protein called PD-1 on the surface of T-cells, which helps the immune system recognize and attack cancer cells more effectively.

    Research 10 of 104

    1. Persistently curly hair phenotype with the use of nivolumab for squamous cell lung cancer Journal of oncology pharmacy practice · 2016 · 19 citations
    2. Nivolumab-Induced Alopecia Areata: A Case Report and Literature Review 2021 · 10 citations
    3. Resolution of paraneoplastic alopecia areata following nivolumab in a patient with metastatic melanoma JAAD case reports · 2023 · 1 citations
    4. A case of bullous pemphigoid in a malignant melanoma patient following an increased Th2/Th1 ratio in peripheral blood cells after nivolumab treatment European Journal of Dermatology · 2023 · 1 citations
    5. Anti-programmed cell death protein 1-induced lichenoid changes of the nail unit: Histopathologic description JAAD Case Reports · 2021 · 12 citations
    6. Eosinophilic folliculitis of the scalp associated with PD‐1/PDL1 inhibitors Journal of Cosmetic Dermatology · 2020 · 9 citations
    7. Cutaneous Toxicities of Advanced Treatment for Cutaneous Melanoma: A Prospective Study from a Single-Center Institution Cancers · 2024 · 3 citations
    8. Immune Cell-Targeting Biologics for Alopecia Areata: A New Paradigm in Precision Medicine Skin Appendage Disorders · 2025
    9. Cemiplimab-Induced Alopecia Areata International Journal of Trichology · 2023
    10. ODP342 Panhypopituitarism Induced by CTLA-4 and PD-1/PD-L1 Inhibitor Immunotherapy Journal of the Endocrine Society · 2022
    All research results →

    Learn

    — no results

    Try a deeper search in learn →

    Community

    — no results

    Try a deeper search in community →